Medicus Pharma Ltd. (MDCXW)
| Market Cap | 4.82M -91.7% |
| Revenue (ttm) | n/a |
| Net Income | -50.91M |
| EPS | -59.35 |
| Shares Out | 1.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45 |
| Open | 0.2410 |
| Previous Close | 0.2000 |
| Day's Range | 0.2410 - 0.2790 |
| 52-Week Range | 0.0111 - 1.4500 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About MDCXW
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was inco... [Read more]
News
Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange
CEO and other insiders lead private investment of $1.25 million, including $750,000 from the CEO, underscoring confidence in the Company's precision oncology-led strategy, anchored by its CD228V deve...
Medicus Pharma downgraded to Hold from Buy at Brookline
Brookline downgraded Medicus Pharma (MDCX) to Hold from Buy.
Medicus Pharma Earnings Call Transcript: Q3 2026
Nine-month losses widened as investment supported the Pfizer CD228V license, while Q3 expenses and net loss declined YoY. Priorities are CD228V development, a proposed SkinJect SPAC transaction, and Teverelix partnerships.
Medicus Pharma Quarterly report: Q3 2026
Medicus Pharma has published its Q3 2026 quarterly earnings report on November 9, 2026.
Medicus Pharma Earnings release: Q3 2026
Medicus Pharma released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Medicus to highlight rational for CD228V co-development, license agreement
Medicus Pharma (MDCX) outlined key highlights for its third quarter 2026 financial performance and business update conference call at 11:30 a.m. Eastern Time today, following the filing of its Quarter...
Medicus Pharma to highlight rationale for proposed SkinJect SPAC transaction
The proposed SkinJect Transaction is intended to establish a separately listed company with its own access to public capital markets and dedicated financing for Gorlin syndrome development, while Medi...
Medicus Pharma to Present at BIO-Europe 2026
Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight ...
Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical dev...
Medicus Pharma enters LOI for Skinject business combination
Medicus Pharma (MDCX) announced that, its wholly-owned subsidiary, Skinject, has entered into a non-binding letter of intent, or LOI, with an undisclosed special purpose acquisition company for a prop...
Medicus Pharma Announces Proposed SkinJectÂź Business Combination and Concurrent Financing
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (âMedicusâ or the âCompanyâ), a precision guided, biotech/life sciences company focused on advancing novel and potent...
Medicus Pharma Proxy statement: Proxy filing
Medicus Pharma filed a proxy statement on October 30, 2026, providing details for shareholder voting and corporate governance matters.
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
Company's Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi Company's Executive Cha...
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance
Medicus Pharma Slides: Corporate presentation
Medicus Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Medicus Pharma Proxy statement: Proxy filing
Medicus Pharma filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Medicus Pharma Ltd trading halted, news pending
19:50 EDT Medicus Pharma (MDCX) Ltd trading halted, news pending
Medicus Pharma cites about $90M raised to advance CD228V, SkinJect, Teverelix
Medicus Pharma (MDCX) announced a shareholder update celebrating its third anniversary, saying approximately $90M raised through equity and debt financing over three years supported clinical developme...
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (âMedicusâ or the âCompanyâ), a precision guided, biotech/life sciences company focused on advancing novel and potent...
Medicus Pharma submits optimized Teverelix registrational protocol to FDA
Medicus Pharma (MDCX) announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration, FDA, for Teverelix, its investigational, n...
Medicus Pharma Submits Optimized TeverelixÂź Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Pro...
Medicus to focus future clinical development of SkinJect on Gorlin syndrome
Medicus Pharma (MDCX) announced that it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and c...
Medicus Pharma Announces Exclusive Development Focus for SkinJectÂź in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
Medicus Pharma price target raised to $1 from 90c at Alliance Global
Alliance Global analyst Matthew Venezia raised the firmâs price target on Medicus Pharma (MDCX) to $1 from 90c and keeps a Buy rating on the shares following a transfer ofâŠ
Medicus Pharma Publishes Abridged Final Phase 2 SkinJectŸ Clinical Study Report (CSR) Results Identifying 200 ”g D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussi...